Meridian acquires POC company Magellan for $66mm in cash
Executive Summary
Meridian Bioscience Inc. acquired point-of-care testing company Magellan Biosciences Inc. (and subsidiary Magellan Diagnostics) from an investor group including Ampersand Capital Partners, Abingworth, Tekla Capital Management, and Boston Community Venture Fund for $66mm in cash (using cash on hand and a new five-year $60mm term loan).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice